$25 Billion Genomics Annual Market in the U.S, President Obama Health Care Reform New Best Friend GenNXeix And Genomics

March, 15, 2012 By Barron Graham Reporting from Baylor College of Medicine Houston Texas —–< Business–Wire>

$25 Billion Genomics Annual Market in the U.S, President Obama Health Care Reform New Best
Friend is GenNXeix And Genomics



44,000 Women in the United States will die this year of metastatic breast cancer
disease. Human epidermal growth factor receptor (HER2 ), will be amplified or
activated in 25 to 30 percent of breast cancers. GenNXeix Biotech Scientist discovered in Houston and Reports that the regulation and the prevention of Breast Cancer and Her2 from spreading with the use of Nanoparticles and ABCG2 (breast cancer resistance protein).

GenNXeix researchers focus on the breast cancer resistance protein, also known as

ABCG2. ABCG2 is a wonderful genomic find that works with ATP-binding cassette (ABC) transporters to combat multidrug resistance better known as ABCG2. Which
allows breast cancer patients chemotherapeutic to work.

GenNXeix develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.

GenNXeix discovered that breast cancer ccurs at multiple levels and involves S1P receptors called sphingosine kinases, S1P phosphatases and S1P lyase. S1P is designed to alter S1P signalling and function in breast cancer.

GenNXeix clinical trial patients who appear phenotypically normal was a essential step toward targeting ABCG2 protein to stop the spreading of breast cancer.


GenNXeix understands that a nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.GenNXeix scientist say this is why GenNXeix and others says that Genomics is a $25 Billion Annual Market in the U.S only.

Genomic information is entering the health care system from the GenNXeix scientific community. Gennxeix clinicians face growing demands from consumers and clear evidence about the value of genomics testing, works with professional societies.

GenNXeix develops evidence base surrounding genetic/genomics applications, including analytic tools, decision support aids and utilization strategies to measure and monitor clinical performance, disseminate and expand best practices from providers – improve approaches to developing the evidence base surrounding genomics applications, including analytic tools, decision support aids and utilization strategies to measure and monitor clinical performance, disseminate and expand best practices.

GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs